A Randomized, Open Label, Phase Ii Study Of Prophylactic Octreotide (Oct) To Prevent/Reduce The Frequency And Severity Of Diarrhea In Patients (Pts) Receiving Lapatinib (Lap) With Capecitabine (Cap) For The Treatment Of Metastatic Breast Cancer (Mbc)